A subset of individuals with DSDs are predisposed to gonadal germ cell tumor (GCT). In this setting, GCT risk varies widely, depending on the DSD molecular etiology and penetrance.
| INTRODUCTION
Differences of Sex Development (DSD) encompass a diverse set of congenital conditions in which the development of chromosomal, gonadal, or anatomic sex is atypical. Although the term "DSD" is commonly used interchangeably with "ambiguous genitalia," only a subset of DSD patients has non-dimorphic (i.e., atypical) genitalia.
Reports dating to the turn of the last century recognized the increased risk of gonadal tumors in some individuals with DSD (Abel, 1891) .
Despite advances in genetic diagnosis, determining the personalized risk of gonadal germ cell tumor (GCT) for an individual with DSD remains a daunting task, with limited attempts to stratify risk by precise molecular etiology. As interpretation becomes increasingly complicated with the rapid identification of novel genetic causes of DSD (Achermann, Domenice, Bachega, Nishi, & Mendonca, 2015) , the clinical geneticist has a critical role to play, participating as a member of a clinical team attempting to estimate the GCT risk for an individual patient with DSD.
Despite advances in genetic diagnosis, determining the personalized risk of gonadal germ cell tumor (GCT) for an individual with DSD remains a daunting task, with limited attempts to stratify risk by precise molecular etiology.
genetic testing can become the primary driver of DSD categorization. The detection of a canonical mutation that causes a known DSD disorder with no minimal GCT risk, for example loss of function in CYP21A, the most common form of congenital adrenal hyperplasia (CAH), mitigates the need for additional clinical investigation including gonadal biopsy, and pathologic analysis. In addition, the number of known causative genes and mutations for DSD is everincreasing, resulting in entities that push the boundaries of the 2006 classification (Baxter et al., 2015; Eggers et al., 2016) . Twenty-five imprecise DSD classification and molecular diagnoses; and (4) challenging histopathology leading to heterogeneous classification of GCT neoplasia.
The decision to pursue gonadectomy in the patient with DSD is based on multiple parameters, including gender identity, gonadal GCT risk, and desire for fertility. Ideally, patient-specific recommendations are made by a formalized interdisciplinary team including minimally geneticists, endocrinologists, behavioral health specialists, and urologists (Palmer et al., 2012) . The benefit of gonadectomy includes both reduced gonadal GCT risk, and reduction of endogenous sex hormone production, if discordant with gender identity. Benefits of gonad retention can include endogenous hormone production congruent with gender identity, preservation of possible future fertility, and delay of the decision until the patient is the age of assent/consent. The parameters used to assign risk level include chromosomal compliment, particularly inclusion of Y-material; gonadal pathology (which requires surgical biopsy or gonadectomy to ascertain); phenotype of the genitals and reproductive organs; the endocrine milieu; and in some cases, the potential risk of syndrome-related complicating medical comorbidities such as adrenal insufficiency or cancer of other organs ( Figure 1 ). Connecting these parameters with molecular etiology and GCT requires a knowledge of germ cell biology.
| Germ cell cancer development
Germ cell development is a highly complex process requiring alignment spatially, temporally, and genetically (recently reviewed by [Hersmus et al., 2017; Tang, Kobayashi, Irie, Dietmann, & Surani, 2016] ). The development of the human germ cell starts with specification of the primordial germ cells (PGC) from other somatic cells around the time of gastrulation (developmental week 2).
Specification is driven by BLIMP1 and SOX17 (Irie et al., 2015) in humans, and PRDM14 in mice (Grabole et al., 2013) . The divergent primary drivers of human and mouse specification are emblematic of broader inter-species sex development variation, which presents challenges to accurate laboratory modeling. PGCs migrate in a cluster along the midline from the proximal epiblast into the genital ridge, guided by KIT/KITLG signaling, and reach their destination by weeks 5-6. Cells that do not reach the genital ridge apoptose. During migration PCGs undergo "licensing" (global demethylation) in preparation for imprinting, and after arrival at the undifferentiated gonad (in the genital ridge) PGCs are referred to as gonocytes (testicular) or oogonia (ovarian). PGCs until this time express several markers that are also histopathological markers of GCT, including OCT 3/4 and PLAP. Next, a cascade of signaling drives sex determination and assigns the developing gonad as future testicle or ovary. SRY and SOX9
are the primary pro-testicular drivers, working through multiple transcription factors including NR5A1 and ZFPM2 (Nikolova & Vilain, 2006) . Mutations in all four genes have been shown to cause DSD.
Ovarian development is both the non-SRY default and proactively driven by signaling pathways, downstream of WNT4/β-catenin, FOXL2, and RSPO1 (Mandel et al., 2008; Parma et al., 2006; Uhlenhaut et al., 2009 amplification. Often a GCT precursor lesion can be identified, either gonadoblastoma (GB) in setting of an ovary or a non-dimorphic gonad, or germ cell neoplasia in situ (GCNIS) in the testicle. We will refer to these lesions as GCNIS/GB. The current testicular germ cell tumor (TGCT) oncogenesis model proposes that GCNIS is present from birth as a defect of fetal development, and is 100% predestined to eventually development into a malignant tumor (mean age 20-35 yo) (Hoei-Hansen, Rajpert-De Meyts, Daugaard, & Skakkebaek,2005) . In contrast, it appears that GB can either be present at birth or develop later in life and only 50% will develop into malignant tumors (Cools, Drop, & Wolffenbuttel, 2006) . However, GCNIS/GB cannot be histologically distinguished from delayed gonocyte development prior to six, or even twelve, months of age (Cools, Looijenga, Wolffenbuttel, & T'Sjoen, 2014) . Gonadal development can be delayed in a number of genetic disorders, including both DSDs and non-DSD syndromes, such as trisomy 21; this prolonged state of gonocyte immaturity increases the risk of oncologic transformation (Cools, Honecker, et al., 2006) .
Gonadal biopsy exclusively for the purposes of GCT risk assessment should therefore be delayed beyond 1 year of age whenever feasible.
| Risk-benefit analysis of gonadectomy
The decision to recommend gonadectomy is individualized when and exquisite sensitivity to platinum-based agents. Ovarian GCTs (OCGT) are much more rare (lifetime risk 0.07%) and also have a high survival rate (95% at 5 years) when treated with platinum-based therapy, despite the difficulty in self-detection of an intra-abdominal tumor (Solheim et al., 2014) . Post-treatment complications of GCT treatment include cardiovascular disease and metabolic syndrome, infertility, and need for hormonal supplementation (Travis et al., 2010) .
From testicular and ovarian GCT, we can infer that gonadal GCT is responsive to treatment and survival is high. Infertility and hormonal treatment are often pre-existing conditions for the DSD patient, but cardiovascular disease is a survivorship risk. Appropriately diagnosed DSD patients have the added of advantage over individuals with dimorphic gonads of knowing they are at risk of cancer, although they may prefer to resolve the concern with gonadectomy. are in fact at higher risk of GCT (Şimşek et al., 2016) .
| GCT risk stratification by 2006 taxonomy
To survey the literature for newer reports of DSD patients and GCNIS/GB rates, we conducted a PubMed search for "disorder of sex Despite these limitations, newer publications suggested no major change to the gonadal tumor risk stratification previously proposed by (Table 2 ). Further searches for specific DSD diagnoses by more precise names (e.g., AIS) revealed additional publications not captured in Figure 4 . Both approaches were using in the following sections, which review the invasive GCT risk for some illustrative causes of DSD.
2 | GCT risk in selected DSDs Lee et al., 2015) . Within the same family, phenotypes can range from mild hypospadias and retained male fertility to clitoral hypertrophy and complete gonadal dysgenesis (Pearlman et al., 2010) . MAP3K1
was first identified as mutated in association with DSD in a family of 11, of which four were 46,XY males with no signs of tumor, and seven were 46,XY females, two of which had dysgerminoma (including the study proband at 7 years old) (Jawaheer et al., 2003) . MAP3K1 variants subtly alter the balance of pro-testicular (SOX9/FGF9) and proovarian (WNT4/β-catenin) signaling in vitro via gain-of-function mutations (Loke et al., 2014) . Upregulation of the MAPK signaling pathway are well described across multiple tumor types (particularly breast cancer) secondary to MAP3K1 loss-of-function mutations (Pham, Angus, & Johnson, 2013 (Cox et al., 2014) . Genital anomalies are found in 74% of patients with SLO, and 65% of those with biochemically confirmed SLO (elevated 7-dehydrocholesterol secondary to defects of DHCR7). SLO external genitalia in 46,XY individuals include typical male, typical female, and the full non-dimorphic genital spectrum between (Kelley & Hennekam, 2000) . Normal testes, absent gonads, and ovotestes have been reported (Kohler, 1983; Lachman, Wright, Whiteman, Herson, & Greenstein, 1991 (Patsner, Mann, & Chumas, 1989 ). An additional patient, a 14-year-old 46,XY male with genetically confirmed SLO, presented with a malignant germinoma of the brain (Oslejskova et al., 2008) . It is intriguing to consider why loss of androgen signaling in the setting of androgen insensitivity increases gonadal GCT risk in the 46,XY individual but, apparently, loss of androgen signaling via decreased androgen synthesis (as in SLO) does not.
| Y-containing turner syndrome
Turner Syndrome patients with Y-containing material, specifically the TSPY region, have a 12-40% risk of GCNIS/GB (Lau et al., 2009; Looijenga et al., 2007) in addition to the UK national cohort study (Table 3) . These publications describe 99 patients, including 26 cases of GCNIS/GB (26.2%), and three patients with dysgerminoma (3.0%). In contrast, a UK cohort study published within the same time frame including 212 patients described five (2.4%) with GCNIS/GB and two (1.0%) with dysgerminoma (Schoemaker et al., 2008) . The differing rates are likely due to reporting or lead-time bias. This high level of discrepancy highlights the difficulty in providing precise guidelines for patients.
Individuals with dysgerminoma ranged in age from 13 to 24 years old, concordant with the model where-in malignant GCT risk increases
with age, and gonadectomy should be considered at puberty.
However, our center has identified dysgerminoma in Y-positive Turner patients as young as 6 and 10 years old (unpublished cases). 
| GCT in non-DSD genetic diagnoses
Increased rates of germ cell tumor have been associated with various non-DSD genetic syndromes. The strongest association is with trisomy 21 (Table 4) . 46,XY individuals with trisomy 21 have decreased risk of solid tumors, with the notable exception of TGCT (SIR 2.9; 95% CI 1.6-4.8) (Hasle, Hriedman, Olsen, & Rasmussen, 2016) . Evaluation of infants with trisomy 21 revealed constitutional delay of germ cell maturation that may be akin to the delayed primordial gonocyte development identified in non-syndromic DSD, and explain the association between trisomy 21 and TGCT (Cools, Honecker, et al., 2006 ). An association has been hypothesized between Russell-Silver Syndrome and GCT on the basis of two case reports. However, it has not been confirmed with larger population-based studies (Funada, Ikeuchi, Yoshida, & Segawa, 2016; Weiss & Garnick, 1981) . SchinzelGiedion syndrome is classically associated with GCT, but specifically with extragonadal mature neonatal sacrocoxygeal teratoma; however, in one report a Schinzel-Giedion associated teratoma contained components of non-germinoma (Kishimoto et al., 2015; Robin, Grace, DeSouza, McDonald-McGinn, & Zackai, 1993) . Overall, the GCT risk associated with Russell-Silver Syndrome is unconvincing, but the GCT risk in trisomy 21 is significant, and presents a research opportunity to better appreciate chromosome 21 influence on sex development in the 46,XY individual.
Increased rates of germ cell tumor have been associated with various non-DSD genetic syndromes. The strongest association is with trisomy 21 (Table 4) . 46,XY individuals with trisomy 21 have decreased risk of solid tumors, with the notable exception of TGCT (SIR 2.9; 95% CI 1.6-4.8).
| Extragonadal cancer predisposition in dimorphic DSDs
Klinefelter Syndrome (47,XXY) is associated with a specific risk of mediastinal GCT. Extragonadal GCTs arise from germ cells that both failed to migrate appropriately to the genital ridge, and failed to apoptose; along with shared underlying disease origin, mediastinal and gondadal GCTs also share genetic signatures including hypomethylation and 12p copy number increases (Oosterhuis, Stoop, Honecker, & Looijenga, 2007) . Unlike gonadal GCTs, mediastinal GCTs have an increased rate of platinum-based therapy resistance secondary to high expression of TP53, resulting in survival of only ∼50% (Bagrodia et al., 2016) . Approximately 8% of men with mediastinal GCT have Klinefelter syndrome (De Sanctis, Fiscina, Soliman, Giovannini, & Yassin, 2013) , and it is important to screen cases of mediastinal GCT for covert Klinefelter. In addition, individuals with Klinefelter syndrome have cancer risks thought to be associated with the additional X-chromosome, including a 19-58-fold risk of breast cancer versus 46,XY men (Brinton, 2011; Ferzoco & Ruddy, 2016 prophylactic resection of remnants (Kovachev, Nikolov, & Mihova, 2014) . All of these cancers are relatively rare, even within these rare populations, but are important to include in genetic counseling and genetic cancer predisposition teaching for patients with these diagnoses.
| CONCLUSIONS
Determining the GCT risk for an individual with a DSD requires precise taxonomical categorization based on karyotype, molecular data, hormonal milieu, external phenotype and gonadal morphology.
More-over, psychosocial factors must be taken into account, including patient comfort with a risk of GCT and self-determination over gonadectomy decisions. These psychosocial factors therefore become particularly challenging in the pediatric setting, where the patient is not yet at age of assent. An interdisciplinary DSD team including specialists from endocrinology, psychology, urology, genetics, and for some discussions, oncology, provides the ideal context for clinical data collection, interpretation, and patient counseling on DSD GCT predisposition.
Molecular diagnosis for DSD conditions is becoming more specific; however, lack of natural history data inhibits the clinician's ability to assign GCT risk level based on genotype. Large, multiinstitutional, prospective studies are required to better quantify the relationship between genetic etiology and development of GCNIS/ GB. But given the frequency of early prophylactic gonadectomy, empirical data is limited, and we must develop alternate approaches.
Individual patient mutations can be modeled in the research setting to examine their effects on germ cell biology and appraise personalized GCT risk. Novel screening tools for GCT, including peripheral blood miRNA testing and non-invasive labeled imaging of gonadal tissue, are in development and have the potential to radically transform screening and surgical guidelines for DSD.
Pending availability of these technologies, the clinical geneticist is the primary resource for timely and rational genetic testing, with expert interpretation. Such data supports the multidisciplinary team's effort to employ more conservative hormonal and surgical approaches while assessing GCT risk.
It is widely held in the dimorphic testicular and ovarian literature that there is no single high-penetrance gene predisposing to GCT. In fact, many of the genes causing DSD are just that, highly penetrant causes of GCT. Any genetic variation in germ cell development significant enough to strongly predispose to GCT will also, by definition, also cause differences in sex development. The wellelucidated breast cancer predisposition genes are analogous, including low-to-high penetrance variants, and a broad spectrum of presenta- and support yet more patient-specific GCT risk stratification in the future. 
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